Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/48718c7b-5ac6-435c-b248-efa0c6cb8a13/

CUE

Cue Biopharma
Chart
32.12 USD
Latest Week 2026-07-24
HealthcareBiotechnologyMICRO
Snapshot 2026-07-26 · 0.4w · Fresh
0.05
OS Score
18.0%
Value
3.0%
Quality
34.0%
Momentum
4/9
F-Score
0.073
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
18.0%ile
P/S
4.1×
P/B
6.2×
FCF Yield
-0.199
SH Yield
-0.230
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
78.00000000
/100 — 1=cheapest
VC2 (Trending Value)
85.00000000
/100
VC3 (Buyback)
85.00000000
/100
Negative FCF yield (-19.9%) — the business is currently cash-consumptive. VC2 score of 85.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
3.0%ile
ROE
-0.904
ROA
-0.632
Net Margin
-0.596
Op Margin
-0.576
GPA
1.057
D/E
0.43
Current
3.57
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
3.096
Stability
0.560
lower=better
Accruals
0.160
lower=better
5yr Consist
No
Conservative balance sheet with D/E of 0.43. Accruals ratio of 0.160 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
34.0%ile
6M Return
181.8%
12M Return
21.3%
12-1 Mom
-4.1%
Risk-Adj
-0.02
Vol 252d
221.1%
Vol 60d
562.2%
↑ Expanding
Max DD 12M
-78.4%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (562%) is expanding vs long-term (221%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.05
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
6.4%
Sector Quality %ile
0.2%
P/B z-score
-0.01
Sector Avg OS
64.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
THC Tenet Healthcare Corporation 97.0% 90.0% 91.0% 81.0%
Factor Interactions
Volatility Expanding
60-day vol (562%) significantly exceeds 252-day (221%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
24.4% avg (4 factors)
Quality
D
36.2% avg (8 factors)
Momentum
C
52.3% avg (4 factors)
Risk
F
0.0% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.050—8—
Value %ile0.180—8—
Quality %ile0.030—8—
Momentum %ile0.340—0—
F-Score4.000—8—
Confidence0.784—8—
Volatility2.211—8—
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Sales
4.12
Price / Book
6.24
FCF Yield
-19.9%
Sales Yield (1/P·S)
0.2683
Shareholder Yield
Div + net buyback / mktcap
-23.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-90.4%
Return on Assets
-63.2%
Net Margin
-59.6%
Operating Margin
-57.6%
Gross Profit / Assets
Novy-Marx GPA
105.7%
Debt / Equity
0.43
Current Ratio
3.57
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.160
MomentumPrice trend strength over different horizons
6M Return
181.8%
12M Return
21.3%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-4.1%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.02
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
309.6%
Earnings Stability (CV)
Lower = more stable
0.560
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
4
Buyback Yield
-23.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
78
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
85
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
85
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity